416 related articles for article (PubMed ID: 15765081)
1. In biomarkers we trust?
Baker M
Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
[No Abstract] [Full Text] [Related]
2. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets.
Bodovitz S; Joos T
Trends Biotechnol; 2004 Jan; 22(1):4-7. PubMed ID: 14690616
[No Abstract] [Full Text] [Related]
3. In the pursuit of industrial proteomics.
Mitchell P
Nat Biotechnol; 2003 Mar; 21(3):233-7. PubMed ID: 12610565
[No Abstract] [Full Text] [Related]
4. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
6. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
7. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.
Razvi ES
IDrugs; 2005 Oct; 8(10):796-8. PubMed ID: 16254794
[No Abstract] [Full Text] [Related]
8. Discovery and development of biomarkers of neurological disease.
Dunckley T; Coon KD; Stephan DA
Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
[TBL] [Abstract][Full Text] [Related]
9. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
10. Private company profiles.
Nat Biotechnol; 2002 Jul; 20 Suppl():BE15-21. PubMed ID: 12089572
[No Abstract] [Full Text] [Related]
11. Carlo Incerti.
Incerti C
Nat Rev Drug Discov; 2008 Aug; 7(8):638. PubMed ID: 18670428
[No Abstract] [Full Text] [Related]
12. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
Napper AD
IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
[No Abstract] [Full Text] [Related]
13. Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry.
Rubin AE; Tummala S; Both DA; Wang C; Delaney EJ
Chem Rev; 2006 Jul; 106(7):2794-810. PubMed ID: 16836299
[No Abstract] [Full Text] [Related]
14. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
15. Growing pains in AIDS drug development.
Herrera S
Nat Biotechnol; 2004 Oct; 22(10):1194. PubMed ID: 15470440
[No Abstract] [Full Text] [Related]
16. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
17. Novel biomarkers of acute kidney toxicity.
Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
[TBL] [Abstract][Full Text] [Related]
18. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
19. Antibacterial drug discovery: is small pharma the solution?
Boggs AF; Miller GH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
[TBL] [Abstract][Full Text] [Related]
20. Venturing into drug discovery.
Steinmetz M
Nat Biotechnol; 1998 May; 16 Suppl():17. PubMed ID: 9591255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
